dactinomycin has been researched along with ciglitazone in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Levine, L | 1 |
Coffey, MJ; Hayes, MM; King, SR; Lane, BR; Markovitz, DM | 1 |
Kim, HK; Kim, HS; Kim, HY; Kim, JR | 1 |
Cheon, H; Choi, SJ; Ji, JD; Kim, HJ; Lee, YH; Rho, YH; Sohn, J; Song, GG; Um, JW | 1 |
6 other study(ies) available for dactinomycin and ciglitazone
Article | Year |
---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Stimulated release of arachidonic acid by agonists of the peroxisome proliferator-activated receptor and retinoic acid receptors.
Topics: Alitretinoin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cell Line; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Indomethacin; Kinetics; Liver; Prostaglandin D2; Prostaglandins A; Pyrazoles; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Sulfonamides; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2001 |
Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects.
Topics: Cell Line; Cells, Cultured; Dactinomycin; Dose-Response Relationship, Drug; HeLa Cells; HIV-1; Humans; Hypoglycemic Agents; Macrophages; Plasmids; Promoter Regions, Genetic; Prostaglandins A; Protein Synthesis Inhibitors; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA Processing, Post-Transcriptional; RNA-Directed DNA Polymerase; RNA, Messenger; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; U937 Cells | 2002 |
Upregulation of LPS-induced chemokine KC expression by 15-deoxy-delta12,14-prostaglandin J2 in mouse peritoneal macrophages.
Topics: Animals; Blotting, Northern; Chemokine CXCL1; Chemokines, CXC; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Flavonoids; Gene Expression; Hypoglycemic Agents; Immunologic Factors; Intercellular Signaling Peptides and Proteins; Lipopolysaccharides; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; PPAR gamma; Prostaglandin D2; Pyrrolidines; RNA Stability; RNA, Messenger; Specific Pathogen-Free Organisms; Thiazolidinediones; Thiocarbamates; Time Factors; Up-Regulation | 2005 |
15-Deoxy-delta12,14-PGJ2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes.
Topics: Arthritis, Rheumatoid; Chromans; Cycloheximide; Dactinomycin; DNA-Binding Proteins; Gene Expression Regulation; Humans; Hypoglycemic Agents; Interleukin-6; Jurkat Cells; Lymphocytes; NF-kappa B; Phosphorylation; PPAR gamma; Prostaglandin D2; Protein Synthesis Inhibitors; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Thiazolidinediones; Trans-Activators; Troglitazone | 2005 |